Volkers Nicole A, Hehenkamp Wouter J K, Smit Patrick, Ankum Willem M, Reekers Jim A, Birnie Erwin
Department of Radiology, Academic Medical Centre G1-235, Meibergdreef 9, Amsterdam, The Netherlands.
J Vasc Interv Radiol. 2008 Jul;19(7):1007-16; quiz 1017. doi: 10.1016/j.jvir.2008.03.001.
To investigate whether uterine artery embolization (UAE) is a cost-effective alternative to hysterectomy for patients with symptomatic uterine fibroids, the authors performed an economic evaluation alongside the multicenter randomized EMMY (EMbolization versus hysterectoMY) trial.
Between February 2002 and February 2004, 177 patients were randomized to undergo UAE (n = 88) or hysterectomy (n = 89) and followed up until 24 months after initial treatment allocation. Conditional on the equivalence of clinical outcome, a cost minimization analysis was performed according to the intention to treat principle. Costs included health care costs inside and outside the hospital as well as costs related to absence from work (societal perspective). Cumulative standardized costs were estimated as volumes multiplied with prices. The nonparametric bootstrap method was used to quantify differences in mean (95% confidence interval [CI]) costs between the strategies.
In total, 81 patients underwent UAE and 75 underwent hysterectomy. In the UAE group, 19 patients (23%) underwent secondary hysterectomies. The mean total costs per patient in the UAE group were significantly lower than those in the hysterectomy group ($11,626 vs $18,563; mean difference, -$6,936 [-37%], 95% CI: -$9,548, $4,281). The direct medical in-hospital costs were significantly lower in the UAE group: $6,688 vs $8,313 (mean difference, -$1,624 [-20%], 95% CI: -$2,605, -$586). Direct medical out-of-hospital and direct nonmedical costs were low in both groups (mean cost difference, $156 in favor of hysterectomy). The costs related to absence from work differed significantly between the treatment strategies in favor of UAE (mean difference, -$5,453; 95% CI: -$7,718, -$3,107). The costs of absence from work accounted for 79% of the difference in total costs.
The 24-month cumulative cost of UAE is lower than that of hysterectomy. From a societal economic perspective, UAE is the superior treatment strategy in women with symptomatic uterine fibroids.
为了研究对于有症状的子宫肌瘤患者,子宫动脉栓塞术(UAE)是否是一种比子宫切除术更具成本效益的替代方案,作者在多中心随机EMMY(栓塞术与子宫切除术对比)试验的同时进行了一项经济评估。
在2002年2月至2004年2月期间,177例患者被随机分配接受UAE(n = 88)或子宫切除术(n = 89),并随访至初始治疗分配后24个月。在临床结局等效的条件下,根据意向性治疗原则进行成本最小化分析。成本包括医院内外的医疗保健成本以及与缺勤相关的成本(社会视角)。累积标准化成本通过数量乘以价格来估算。采用非参数自助法来量化两种策略之间平均(95%置信区间[CI])成本的差异。
总共81例患者接受了UAE,75例接受了子宫切除术。在UAE组中,19例患者(23%)接受了二次子宫切除术。UAE组中每位患者的平均总成本显著低于子宫切除术组(11,626美元对18,563美元;平均差异, - 6,936美元[-37%],95%CI: - 9,548美元,4,281美元)。UAE组的直接住院医疗成本显著更低:6,688美元对8,313美元(平均差异, - 1,624美元[-20%],95%CI: - 2,605美元, - 586美元)。两组的直接院外医疗成本和直接非医疗成本都较低(平均成本差异,有利于子宫切除术156美元)。与缺勤相关的成本在两种治疗策略之间有显著差异,有利于UAE(平均差异, - 5,453美元;95%CI: - 7,718美元, - 3,107美元)。缺勤成本占总成本差异的79%。
UAE的24个月累积成本低于子宫切除术。从社会经济角度来看,UAE是有症状子宫肌瘤女性的更优治疗策略。